News Takeda hurries $62bn Shire acquisition, calls investor vote ... Takeda will hold an investor vote on its $62 billion acquisition of Shire next month, and aims to close the deal on January 8.
News Takeda CEO confident about Shire merger Takeda’s CEO has said he is confident that its $62 billion acquisition of Shire will go ahead, despite a rebellion from a dissident group of shareholders.
News Novartis to buy cancer drug firm Endocyte for $2.1bn Novartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash.
News Mundipharma buys Spanish biosimilars firm Cinfa Biotech Mundipharma, a network of independent pharma companies, has bought Spanish biosimilars development company Cinfa Biotech.
News Alexion buys rare diseases biotech Syntimmune for up to $1.2... Alexion is to buy rare diseases biotech Syntimmune and its experimental drug for a rare kind of anaemia, in a deal worth up $1.2 billion.
News Takeda could sell Shire eye care business after merger Takeda could be considering selling Shire’s eye care business after their $62 billion merger next year to cut debts, according to press reports.
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends